Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro

References

• Barski OA, Tipparaju SM, Bhatnagar A. (2008). The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 40:553–624.
   PubMed Web of Science ®Google Scholar
• Breyer-Pfaff U, Martin HJ, Ernst M, Maser E. (2004). Enantioselectivity of carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone by tissue fractions from human and rat and by enzymes isolated from human liver. Drug Metab Dispos 32:915–922.
   PubMed Web of Science ®Google Scholar
• Davies NM. (1997). Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition? Clin Pharmacokinet 33:404–416.
   PubMed Web of Science ®Google Scholar
• Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR. (1984). Metabolism of nabumetone (BRL 14777) by various species including man. Xenobiotica 14:327–337.
   PubMed Web of Science ®Google Scholar
• Hedner T, Samulesson O, Währborg P, Wadenvik H, Ung KA, Ekbom A. (2004). Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 64:2315–43; discussion 2344.
   PubMed Web of Science ®Google Scholar
• Hoffmann F, Maser E. (2007). Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev 39:87–144.
   PubMed Web of Science ®Google Scholar
• Hult M, Nobel CS, Abrahmsen L, Nicoll-Griffith DA, Jörnvall H, Oppermann UC. (2001). Novel enzymological profiles of human 11β-hydroxysteroid dehydrogenase type 1. Chem Biol Interact 130–132:805–814.
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147–171.
   PubMed Web of Science ®Google Scholar
• Kallberg Y, Oppermann U, Persson B. (2010). Classification of the short-chain dehydrogenase/reductase superfamily using hidden Markov models. FEBS J 277:2375–2386.
   PubMed Web of Science ®Google Scholar
• Kassner N, Huse K, Martin HJ, Gödtel-Armbrust U, Metzger A, Meineke I, Brockmöller J, Klein K, Zanger UM, Maser E, Wojnowski L. (2008). Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36:2113–2120.
   PubMed Web of Science ®Google Scholar
• Kobylinska K, Barlinska M, Kobylinska M. (2003). Analysis of nabumetone in human plasma by HPLC. Application to single dose pharmacokinetic studies. J Pharm Biomed Anal 32:323–328.
   PubMed Web of Science ®Google Scholar
• Liu J, Wen G, Cao D. (2009). Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives. Recent Pat Anticancer Drug Discov 4:246–253.
   Google Scholar
• Malátková P, Maser E, Wsól V. (2010). Human carbonyl reductases. Curr Drug Metab 11:639–658.
   PubMed Web of Science ®Google Scholar
• Mangan FR, Flack JD, Jackson D. (1987). Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology. Am J Med 83:6–10.
   PubMed Web of Science ®Google Scholar
• Martin HJ, Breyer-Pfaff U, Wsol V, Venz S, Block S, Maser E. (2006). Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos 34:464–470.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Nemoto E, Hasegawa T, Akimoto M, Sugibayashi K. (2011). In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull 34:734–739.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Shintani S, Hara A. (2006). Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab Pharmacokinet 21:1–18.
   PubMed Web of Science ®Google Scholar
• McMahon FG, Vargas R, Ryan JR, Fitts DA. (1987). Nabumetone kinetics in the young and elderly. Am J Med 83:92–95.
   PubMed Web of Science ®Google Scholar
• Nobilis M, Kopecký J, Kvetina J, Svoboda Z, Pour M, Kunes J, Holcapek M, Kolárová L. (2003). Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection. J Pharm Biomed Anal 32:641–656.
   PubMed Web of Science ®Google Scholar
• Nobilis M, Holcapek M, Kolárová L, Kopecký J, Kunes M, Svoboda Z, Kvetina J. (2004). Identification and determination of phase II nabumetone metabolites by high-performance liquid chromatography with photodiode array and mass spectrometric detection. J Chromatogr A 1031:229–236.
   PubMed Web of Science ®Google Scholar
• Nobilis M, Holmanová V, Szotáková B, Chamseddin Ch, Jira T, Matoušová E, Mikušek J, Kuneš J, Pour M. (2012). Chiral high-performance liquid chromatographic determination of nabumetone phase I metabolites: Stereospecificity of carbonyl reducing enzymes involved in nabumetone biotransformation. J Chromatogr B Submitted.
   Google Scholar
• Odermatt A, Nashev LG. (2010). The glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations. J Steroid Biochem Mol Biol 119:1–13.
   PubMed Web of Science ®Google Scholar
• Ohara H, Miyabe Y, Deyashiki Y, Matsuura K, Hara A. (1995). Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 50:221–227.
   PubMed Web of Science ®Google Scholar
• Rosemond MJ, Walsh JS. (2004). Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab Rev 36:335–361.
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Tucker GT. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140–148.
   PubMed Web of Science ®Google Scholar
• Sambrook J, MacCallum P. (2001). Molecular cloning: A laboratory manual. 3rd edition. New York: CSH Press.
   Google Scholar
• Skarydová L, Skarka A, Solich P, Wsól V. (2010). Enzyme stereospecificity as a powerful tool in searching for new enzymes. Curr Drug Metab 11:547–559.
   PubMed Web of Science ®Google Scholar
• Steckelbroeck S, Oyesanmi B, Jin Y, Lee SH, Kloosterboer HJ, Penning TM. (2006). Tibolone metabolism in human liver is catalyzed by 3α/3β-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily. J Pharmacol Exp Ther 316:1300–1309.
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Hofmann U, Klein K, Mürdter T, Schwab M, Zanger UM. (2009). A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 37:1017–1024.
   PubMed Web of Science ®Google Scholar
• Wsól V, Szotáková B, Skálová L, Cepková H, Kvasnicková E. (2000). The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin. Enantiomer 5:263–270.
   PubMedGoogle Scholar